These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

166 related articles for article (PubMed ID: 36010354)

  • 1. The Role of Fluorescence In Situ Hybridization in the Surveillance of Non-Muscle Invasive Bladder Cancer: An Updated Systematic Review and Meta-Analysis.
    Zheng W; Lin T; Chen Z; Cao D; Bao Y; Zhang P; Yang L; Wei Q
    Diagnostics (Basel); 2022 Aug; 12(8):. PubMed ID: 36010354
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Intravesical Bacillus Calmette-Guérin with interferon-alpha versus intravesical Bacillus Calmette-Guérin for treating non-muscle-invasive bladder cancer.
    Shepherd AR; Shepherd E; Brook NR
    Cochrane Database Syst Rev; 2017 Mar; 3(3):CD012112. PubMed ID: 28268259
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Maintenance versus non-maintenance intravesical Bacillus Calmette-Guerin instillation for non-muscle invasive bladder cancer: A systematic review and meta-analysis of randomized clinical trials.
    Chen S; Zhang N; Shao J; Wang X
    Int J Surg; 2018 Apr; 52():248-257. PubMed ID: 29499363
    [TBL] [Abstract][Full Text] [Related]  

  • 4. The Role of Fluorescence In Situ Hybridization for Predicting Recurrence after Adjuvant bacillus Calmette-Guérin in Patients with Intermediate and High Risk Nonmuscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis of Individual Patient Data.
    Liem EIML; Oddens JR; Vernooij RWM; Li R; Kamat A; Dinney CP; Mengual L; Alcaraz A; Izquierdo L; Savic S; Thalmann GN; Bubendorf L; Sylvester RJ; de Reijke TM
    J Urol; 2020 Feb; 203(2):283-291. PubMed ID: 31549936
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Evidence-based Assessment of Current and Emerging Bladder-sparing Therapies for Non-muscle-invasive Bladder Cancer After Bacillus Calmette-Guerin Therapy: A Systematic Review and Meta-analysis.
    Kamat AM; Lerner SP; O'Donnell M; Georgieva MV; Yang M; Inman BA; Kassouf W; Boorjian SA; Tyson MD; Kulkarni GS; Chang SS; Konety BR; Svatek RS; Balar A; Witjes JA
    Eur Urol Oncol; 2020 Jun; 3(3):318-340. PubMed ID: 32201133
    [TBL] [Abstract][Full Text] [Related]  

  • 6. European Association of Urology Guidelines on Non-muscle-invasive Bladder Cancer (TaT1 and Carcinoma In Situ) - 2019 Update.
    Babjuk M; Burger M; Compérat EM; Gontero P; Mostafid AH; Palou J; van Rhijn BWG; Rouprêt M; Shariat SF; Sylvester R; Zigeuner R; Capoun O; Cohen D; Escrig JLD; Hernández V; Peyronnet B; Seisen T; Soukup V
    Eur Urol; 2019 Nov; 76(5):639-657. PubMed ID: 31443960
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Surveillance of non-muscle invasive bladder cancer using fluorescence in situ hybridization: Protocol for a systematic review and meta-analysis.
    Lin T; Jin H; Gong L; Yu R; Sun S; Yang L; Zhang P; Han P; Cheng J; Liu L; Wei Q
    Medicine (Baltimore); 2019 Feb; 98(7):e14573. PubMed ID: 30762807
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The prognostic value of cytology and fluorescence in situ hybridization in the follow-up of nonmuscle-invasive bladder cancer after intravesical Bacillus Calmette-Guérin therapy.
    Savic S; Zlobec I; Thalmann GN; Engeler D; Schmauss M; Lehmann K; Mattarelli G; Eichenberger T; Dalquen P; Spieler P; Schoenegg R; Gasser TC; Sulser T; Forster T; Zellweger T; Casella R; Bubendorf L
    Int J Cancer; 2009 Jun; 124(12):2899-904. PubMed ID: 19230026
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intravesical Chemohyperthermia vs. Bacillus Calmette-Guerin Instillation for Intermediate- and High-Risk Non-muscle Invasive Bladder Cancer: A Systematic Review and Meta-Analysis.
    Zhao H; Chan VW; Castellani D; Chan EO; Ong WLK; Peng Q; Moschini M; Krajewski W; Pradere B; Ng CF; Enikeev D; Vasdev N; Ekin G; Sousa A; Leon J; Guerrero-Ramos F; Tan WS; Kelly J; Shariat SF; Witjes JA; Teoh JY
    Front Surg; 2021; 8():775527. PubMed ID: 34888347
    [No Abstract]   [Full Text] [Related]  

  • 10. Combination of Intravesical Bacille Calmette-Guérin and Chemotherapy vs. Bacille Calmette-Guérin Alone in Non-muscle Invasive Bladder Cancer: A Meta-Analysis.
    Huang D; Jin YH; Weng H; Huang Q; Zeng XT; Wang XH
    Front Oncol; 2019; 9():121. PubMed ID: 30881921
    [No Abstract]   [Full Text] [Related]  

  • 11. Prognostic role of pretreatment neutrophil-to-lymphocyte ratio (NLR) in patients with non-muscle-invasive bladder cancer (NMIBC): A systematic review and meta-analysis.
    Vartolomei MD; Porav-Hodade D; Ferro M; Mathieu R; Abufaraj M; Foerster B; Kimura S; Shariat SF
    Urol Oncol; 2018 Sep; 36(9):389-399. PubMed ID: 29884342
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Systematic Review of the Therapeutic Efficacy of Bladder-preserving Treatments for Non-muscle-invasive Bladder Cancer Following Intravesical Bacillus Calmette-Guérin.
    Li R; Sundi D; Zhang J; Kim Y; Sylvester RJ; Spiess PE; Poch MA; Sexton WJ; Black PC; McKiernan JM; Steinberg GD; Kamat AM; Gilbert SM
    Eur Urol; 2020 Sep; 78(3):387-399. PubMed ID: 32143924
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Efficacy and toxicity in scheduled intravesical gemcitabine versus Bacille Calmette-Guérin for Ta and T1 bladder cancer: a systematic review and meta-analysis.
    Lu JL; Xia QD; Liu CQ; Sun JX; Yang YY; Hu HL; Wang SG
    Transl Cancer Res; 2021 Jun; 10(6):2849-2858. PubMed ID: 35116595
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Gender-specific Differences in Recurrence of Non-muscle-invasive Bladder Cancer: A Systematic Review and Meta-analysis.
    Uhlig A; Strauss A; Seif Amir Hosseini A; Lotz J; Trojan L; Schmid M; Uhlig J
    Eur Urol Focus; 2018 Dec; 4(6):924-936. PubMed ID: 28888813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A Phase 1/2 Single-arm Clinical Trial of Recombinant Bacillus Calmette-Guérin (BCG) VPM1002BC Immunotherapy in Non-muscle-invasive Bladder Cancer Recurrence After Conventional BCG Therapy: SAKK 06/14.
    Rentsch CA; Thalmann GN; Lucca I; Kwiatkowski M; Wirth GJ; Strebel RT; Engeler D; Pedrazzini A; Hüttenbrink C; Schultze-Seemann W; Torpai R; Bubendorf L; Wicki A; Roth B; Bosshard P; Püschel H; Boll DT; Hefermehl L; Roghmann F; Gierth M; Ribi K; Schäfer S; Hayoz S
    Eur Urol Oncol; 2022 Apr; 5(2):195-202. PubMed ID: 35012889
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Determining optimal maintenance schedules for adjuvant intravesical bacillus Calmette-Guerin immunotherapy in non-muscle-invasive bladder cancer: a systematic review and network meta-analysis.
    Huang Z; Liu H; Wang Y; Zhang C; Xu T
    Curr Med Res Opin; 2017 Aug; 33(8):1379-1387. PubMed ID: 28471272
    [TBL] [Abstract][Full Text] [Related]  

  • 17. EAU Guidelines on Non-Muscle-invasive Urothelial Carcinoma of the Bladder: Update 2016.
    Babjuk M; Böhle A; Burger M; Capoun O; Cohen D; Compérat EM; Hernández V; Kaasinen E; Palou J; Rouprêt M; van Rhijn BWG; Shariat SF; Soukup V; Sylvester RJ; Zigeuner R
    Eur Urol; 2017 Mar; 71(3):447-461. PubMed ID: 27324428
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of the combination therapy of bacillus Calmette-Guérin and mitomycin C with the monotherapy for non-muscle-invasive bladder cancer: a meta-analysis.
    Lan Y; Liu D; Lin M
    Neoplasma; 2016; 63(6):967-976. PubMed ID: 27596297
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Xpert bladder cancer monitor in surveillance of bladder cancer: Systematic review and meta-analysis.
    Sharma G; Sharma A; Krishna M; Devana SK; Singh SK
    Urol Oncol; 2022 Apr; 40(4):163.e1-163.e9. PubMed ID: 34535354
    [TBL] [Abstract][Full Text] [Related]  

  • 20.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 9.